BTC Class Might Not Happen Soon But FDA Working On Specific Proposal
Executive Summary
Stakeholders in the concept of creating a behind-the-counter status for some drugs are at loggerheads on the need for a BTC class but agree on one point - FDA will need a long time to reach a decision on the issue
You may also be interested in...
FDA Plans Behind-The-Counter Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.